Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer's stock underperforms the S&P 500, facing patent expirations and competition, yet offers a 6.3% forward dividend yield. Despite a positive Q3 earnings surprise, profitability remains weaker ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer's diverse operations put it in an excellent position to grow in the long run. It doesn't have a top weight loss treatment on the market, but that could change. Its above-average dividend yield ...

On Thursday, Pfizer Inc (PFE) stock saw a modest uptick, ending the day at $27.46 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.36. The stock opened at $27.53 and ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Pfizer reported an adjusted EPS of $1.06, exceeding estimates by over 72%. Revenue reached $17.7 billion, marking a 32% year ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the ...

Company CEO Albert Bourla said Pfizer would consider “any good ideas” that create value, but argued it has already made ...

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...